Clinical-stage biotechnology company PharmAust (ASX:PAA) has provided a four-month progress update on the ongoing 12-month Open-Label Extension study in patients with Amyotrophic Lateral Sclerosis. …
PharmAust says reports positive interim study results from study in ALS
August 26, 2024 Australian Biotech
Latest Video
New Stories
-
Nyrada commences recruitment for phase one clinical trial
March 17, 2025 - -
Neurizon Therapeutics updates investors on initiatives to lift clinical hold
March 17, 2025 - - Australian Biotech -
Radiopharm Theranostics says new data confirms positive tumour uptake
March 17, 2025 - - Australian Biotech -
Race secures ethics approval for RC220 Phase 1 solid tumour trial
March 17, 2025 - - Australian Biotech -
TGA approves Novartis therapy for most commonly diagnosed type of early breast cancer
March 17, 2025 - - Latest News -
Doctor group changes position on weight-loss therapies and the PBS
March 17, 2025 - - Latest News -
In 2025, the US is more likely to adopt PBS pricing policies than oppose them
March 17, 2025 - - Latest News